Compare
Utah Medical Products Inc vs Interpace Biosciences, Inc. vs Retractable Technologies Inc vs Cytosorbents Corp
| Latest fiscal year | Utah Medical Products Inc UTMD | Interpace Biosciences, Inc. IDXG | Retractable Technologies Inc RVP | Cytosorbents Corp CTSO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $38.52M | $38.73M | $38.27M | $37.06M |
| Revenue growth (YoY) | -5.8% | -17.5% | +15.8% | +4.1% |
| Gross margin | 57.1% | 62.3% | 0.1% | 71.5% |
| Operating margin | 29.6% | 10.5% | -55.3% | -39.8% |
| Net margin | 29.3% | 63.5% | -32.8% | -22.1% |
| Net income | $11.29M | $24.57M | -$12.57M | -$8.20M |
| EPS (Diluted) | $3.48 | $0.89 | -$0.43 | -$0.13 |
| Operating cash flow | $14.69M | $5.83M | -$7.06M | -$12.38M |
| Free cash flow | $14.32M | $5.47M | n/a | -$12.54M |
| Cash & equivalents | $85.76M | $2.50M | $2.59M | $6.25M |
| Total assets | $122.54M | $33.84M | $142.63M | $44.18M |
| Total liabilities | $3.27M | $11.47M | $68.26M | $38.28M |
| Shareholders' equity | $119.27M | $22.36M | $74.38M | $5.90M |
| Return on year-end equity | 9.5% | 109.9% | -16.9% | -138.9% |
| Shares outstanding | 3.19M | 4.43M | 29.94M | 62.80M |
Revenue, most recent five fiscal years
| Fiscal year | Utah Medical Products Inc | Interpace Biosciences, Inc. | Retractable Technologies Inc | Cytosorbents Corp |
|---|---|---|---|---|
| Latest | $38.52M Ended 2025-12-31 | $38.73M Ended 2025-12-31 | $38.27M Ended 2025-12-31 | $37.06M Ended 2025-12-31 |
| 1 year earlier | $40.90M Ended 2024-12-31 | $46.93M Ended 2024-12-31 | $33.05M Ended 2024-12-31 | $35.59M Ended 2024-12-31 |
| 2 years earlier | $50.22M Ended 2023-12-31 | $40.04M Ended 2023-12-31 | $43.60M Ended 2023-12-31 | $31.08M Ended 2023-12-31 |
| 3 years earlier | $52.28M Ended 2022-12-31 | $31.84M Ended 2022-12-31 | $94.82M Ended 2022-12-31 | $34.69M Ended 2022-12-31 |
| 4 years earlier | $49.05M Ended 2021-12-31 | $33.12M Ended 2021-12-31 | $188.38M Ended 2021-12-31 | $43.17M Ended 2021-12-31 |